Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 439

1.

Vancomycin-resistance gene cluster, vanC, in the gut microbiome of acute leukemia patients undergoing intensive chemotherapy.

Rashidi A, Zhu Z, Kaiser T, Manias DA, Holtan SG, Rehman TU, Weisdorf DJ, Khoruts A, Dunny GM, Staley C.

PLoS One. 2019 Oct 10;14(10):e0223890. doi: 10.1371/journal.pone.0223890. eCollection 2019.

2.

SEMIPARAMETRIC REGRESSION MODEL FOR RECURRENT BACTERIAL INFECTIONS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION.

Lee CH, Huang CY, DeFor TE, Brunstein CG, Weisdorf DJ, Luo X.

Stat Sin. 2019;29(3):1489-1509. doi: 10.5705/ss.202017.0397.

3.

HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis.

Meybodi MA, Cao W, Luznik L, Bashey A, Zhang X, Romee R, Saber W, Hamadani M, Weisdorf DJ, Chu H, Rashidi A.

Blood Adv. 2019 Sep 10;3(17):2581-2585. doi: 10.1182/bloodadvances.2019000614. Review.

4.

Pediatric acute GVHD: clinical phenotype and response to upfront steroids.

MacMillan ML, Holtan SG, Rashidi A, DeFor TE, Blazar BR, Weisdorf DJ.

Bone Marrow Transplant. 2019 Sep 2. doi: 10.1038/s41409-019-0651-9. [Epub ahead of print]

PMID:
31477785
5.

Risk of venous thromboembolism in patients with non-Hodgkin lymphoma surviving blood or marrow transplantation.

Gangaraju R, Chen Y, Hageman L, Wu J, Francisco L, Kung M, Ness E, Parman M, Weisdorf DJ, Forman SJ, Arora M, Armenian SH, Bhatia S.

Cancer. 2019 Aug 30. doi: 10.1002/cncr.32488. [Epub ahead of print]

PMID:
31469420
6.

Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond.

Pasquini MC, Srivastava A, Ahmed SO, Aljurf M, Atsuta Y, Doleysh C, Galeano S, Gluckman E, Greinix H, Hale G, Hari P, Hashmi SK, Kamani N, Laughlin MJ, Niederwieser D, Seber A, Szer J, Snowden JA, Van Biesen K, Watry P, Weisdorf DJ, Apperley J.

Hematol Oncol Stem Cell Ther. 2019 Aug 20. pii: S1658-3876(19)30054-8. doi: 10.1016/j.hemonc.2019.08.001. [Epub ahead of print]

7.

Specific gut microbiota changes heralding bloodstream infection and neutropenic fever during intensive chemotherapy.

Rashidi A, Kaiser T, Graiziger C, Holtan SG, Rehman TU, Weisdorf DJ, Khoruts A, Staley C.

Leukemia. 2019 Aug 22. doi: 10.1038/s41375-019-0547-0. [Epub ahead of print] No abstract available.

PMID:
31439944
8.

The association of CMV with NK-cell reconstitution depends on graft source: results from BMT CTN-0201 samples.

Rashidi A, Luo X, Cooley S, Anasetti C, Waller EK, Brunstein CG, Cichocki F, Weisdorf DJ, Miller JS.

Blood Adv. 2019 Aug 27;3(16):2465-2469. doi: 10.1182/bloodadvances.2019000298. No abstract available.

9.

Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report.

Wu J, Chen Y, Hageman L, Francisco L, Ness EC, Parman M, Kung M, Watson JA, Weisdorf DJ, Snyder DS, McGlave PB, Forman SJ, Arora M, Armenian SH, Bhatia R, Bhatia S.

Cancer. 2019 Aug 14. doi: 10.1002/cncr.32443. [Epub ahead of print]

PMID:
31412155
10.

Hematopoietic Cell Transplant-Related Toxicities and Mortality in Frail Recipients.

Pamukcuoglu M, Bhatia S, Weisdorf DJ, DeFor TE, Ustun C, Nayar M, Holtan SG, Jurdi NE, Thyagarajan B, Brunstein CG, Bachanova V, Warlick ED, Severseike B, Te HS, Lund T, Arora M.

Biol Blood Marrow Transplant. 2019 Aug 5. pii: S1083-8791(19)30502-6. doi: 10.1016/j.bbmt.2019.07.030. [Epub ahead of print]

PMID:
31394273
11.

Early E. casseliflavus gut colonization and outcomes of allogeneic hematopoietic cell transplantation.

Rashidi A, Ebadi M, Shields-Cutler RR, Kruziki K, Manias DA, Barnes AMT, DeFor TE, Ferrieri P, Young JH, Knights D, Blazar BR, Weisdorf DJ, Dunny GM.

PLoS One. 2019 Aug 8;14(8):e0220850. doi: 10.1371/journal.pone.0220850. eCollection 2019.

12.

Stress responses, M2 macrophages, and a distinct microbial signature in fatal intestinal acute graft-versus-host disease.

Holtan SG, Shabaneh A, Betts BC, Rashidi A, MacMillan ML, Ustun C, Amin K, Vaughn BP, Howard J, Khoruts A, Arora M, DeFor TE, Johnson D, Blazar BR, Weisdorf DJ, Wang J.

JCI Insight. 2019 Aug 8;5. pii: 129762. doi: 10.1172/jci.insight.129762.

13.

Ruxolitinib combined with chemotherapy can eradicate chemorefractory central nervous system acute lymphoblastic leukaemia.

Ebadi M, Wasko J, Weisdorf DJ, Gordon PM, Rashidi A.

Br J Haematol. 2019 Oct;187(1):e24-e27. doi: 10.1111/bjh.16142. Epub 2019 Aug 5. No abstract available.

PMID:
31385290
14.

Outcomes and Predictors of Response in Steroid-Refractory Acute Graft-versus-Host Disease.

Rashidi A, DeFor TE, Holtan SG, Blazar BR, Weisdorf DJ, MacMillan ML.

Biol Blood Marrow Transplant. 2019 Jul 17. pii: S1083-8791(19)30449-5. doi: 10.1016/j.bbmt.2019.07.017. [Epub ahead of print]

PMID:
31325587
15.

Validation of Minnesota acute graft-versus-host disease Risk Score.

MacMillan ML, DeFor TE, Holtan SG, Rashidi A, Blazar BR, Weisdorf DJ.

Haematologica. 2019 Jul 18. pii: haematol.2019.220970. doi: 10.3324/haematol.2019.220970. [Epub ahead of print]

16.

Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors: A Report from the Blood or Marrow Transplant Survivor Study.

Gangaraju R, Chen Y, Hageman L, Wu J, Francisco L, Battles K, Kung M, Ness E, Parman M, Weisdorf DJ, Forman SJ, Arora M, Armenian SH, Bhatia S.

Biol Blood Marrow Transplant. 2019 Jul 3. pii: S1083-8791(19)30416-1. doi: 10.1016/j.bbmt.2019.06.032. [Epub ahead of print]

PMID:
31278995
17.

First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia.

Cooley S, He F, Bachanova V, Vercellotti GM, DeFor TE, Curtsinger JM, Robertson P, Grzywacz B, Conlon KC, Waldmann TA, McKenna DH, Blazar BR, Weisdorf DJ, Miller JS.

Blood Adv. 2019 Jul 9;3(13):1970-1980. doi: 10.1182/bloodadvances.2018028332.

18.

Dynamic Graft-versus-Host Disease-Free, Relapse-Free Survival: Multistate Modeling of the Morbidity and Mortality of Allotransplantation.

Holtan SG, Zhang L, DeFor TE, Bejanyan N, Arora M, Rashidi A, Lazaryan A, Kotiso F, Blazar BR, Wagner JE, Brunstein CG, MacMillan ML, Weisdorf DJ.

Biol Blood Marrow Transplant. 2019 Sep;25(9):1884-1889. doi: 10.1016/j.bbmt.2019.05.015. Epub 2019 May 22.

PMID:
31128328
19.

Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical Donor?

Perales MA, Tomlinson B, Zhang MJ, St Martin A, Beitinjaneh A, Gibson J, Hogan W, Kekre N, Lazarus H, Marks D, McGuirk J, Romee R, Solh M, Wagner JE, Weisdorf DJ, de Lima M, Eapen M.

Haematologica. 2019 May 17. pii: haematol.2018.215202. doi: 10.3324/haematol.2018.215202. [Epub ahead of print]

20.

Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.

Ustun C, Le-Rademacher J, Wang HL, Othus M, Sun Z, Major B, Zhang MJ, Storrick E, Lafky JM, Chow S, Mrózek K, Attar EC, Nand S, Bloomfield CD, Cripe LD, Tallman MS, Appelbaum F, Larson RA, Marcucci G, Roboz GJ, Uy GL, Stone RM, Jatoi A, Shea TC, de Lima M, Foran JM, Sandmaier BM, Litzow MR, Erba HP, Hurria A, Weisdorf DJ, Artz AS.

Leukemia. 2019 May 9. doi: 10.1038/s41375-019-0477-x. [Epub ahead of print]

PMID:
31073153
21.

Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond.

Pasquini MC, Srivastava A, Ahmed SO, Aljurf M, Atsuta Y, Doleysh C, Galeano S, Gluckman E, Greinix H, Hale GA, Hari P, Hashmi SK, Kamani N, Laughlin MJ, Niederwieser D, Seber A, Szer J, Snowden JA, Van Biesen K, Watry P, Weisdorf DJ, Apperley J.

Biol Blood Marrow Transplant. 2019 May 6. pii: S1083-8791(19)30286-1. doi: 10.1016/j.bbmt.2019.05.002. [Epub ahead of print]

22.

Haptoglobin genotype and gut barrier-related complications of allogeneic hematopoietic cell transplantation.

Rashidi A, Allen T, Shanley R, Ebadi M, Weisdorf DJ.

Bone Marrow Transplant. 2019 May 8. doi: 10.1038/s41409-019-0540-2. [Epub ahead of print] No abstract available.

PMID:
31068658
23.

GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia.

Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Ahmed I, Aljurf M, Askar M, Auletta JJ, Bhatt V, Bredeson C, Chhabra S, Gadalla S, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Inamoto Y, Kitko C, Khandelwal P, MacMillan ML, Majhail N, Marks DI, Mehta P, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Qayed M, Rangarajan H, Ringden O, Saad A, Savani BN, Seo S, Shah A, Shah N, Schultz KR, Solh M, Spitzer T, Szer J, Teshima T, Verdonck LF, Williams KM, Wirk B, Wagner J, Yared JA, Weisdorf DJ.

Blood Adv. 2019 May 14;3(9):1441-1449. doi: 10.1182/bloodadvances.2018030171.

24.

Dysbiosis patterns during re-induction/salvage versus induction chemotherapy for acute leukemia.

Rashidi A, Kaiser T, Shields-Cutler R, Graiziger C, Holtan SG, Rehman TU, Wasko J, Weisdorf DJ, Dunny G, Khoruts A, Staley C.

Sci Rep. 2019 Apr 15;9(1):6083. doi: 10.1038/s41598-019-42652-6.

25.

Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL.

Felices M, Kodal B, Hinderlie P, Kaminski MF, Cooley S, Weisdorf DJ, Vallera DA, Miller JS, Bachanova V.

Blood Adv. 2019 Mar 26;3(6):897-907. doi: 10.1182/bloodadvances.2018029371.

26.

Late mortality in blood or marrow transplant survivors with venous thromboembolism: report from the Blood or Marrow Transplant Survivor Study.

Gangaraju R, Chen Y, Hageman L, Wu J, Francisco L, Kung M, Ness E, Parman M, Weisdorf DJ, Forman SJ, Arora M, Armenian SH, Bhatia S.

Br J Haematol. 2019 Jul;186(2):367-370. doi: 10.1111/bjh.15866. Epub 2019 Mar 18. No abstract available.

PMID:
30883690
27.

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).

Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J.

Lancet Haematol. 2019 Mar;6(3):e132-e143. doi: 10.1016/S2352-3026(18)30221-7.

PMID:
30824040
28.

Adaptive NK cell reconstitution is associated with better clinical outcomes.

Cichocki F, Taras E, Chiuppesi F, Wagner JE, Blazar BR, Brunstein C, Luo X, Diamond DJ, Cooley S, Weisdorf DJ, Miller JS.

JCI Insight. 2019 Jan 24;4(2). pii: 125553. doi: 10.1172/jci.insight.125553. [Epub ahead of print]

29.

Predictive value of disease risk comorbidity index for overall survival after allogeneic hematopoietic transplantation.

Bejanyan N, Brunstein CG, Cao Q, Lazaryan A, Ustun C, Warlick ED, Arora M, Wagner JE, Weisdorf DJ.

Blood Adv. 2019 Feb 12;3(3):230-236. doi: 10.1182/bloodadvances.2018018549.

30.

Monocyte Subpopulation Recovery as Predictors of Hematopoietic Cell Transplantation Outcomes.

Turcotte LM, Cao Q, Cooley SA, Curtsinger J, Holtan SG, Luo X, Yingst A, Weisdorf DJ, Blazar BR, Miller JS, Wagner JE, Verneris MR.

Biol Blood Marrow Transplant. 2019 May;25(5):883-890. doi: 10.1016/j.bbmt.2019.01.003. Epub 2019 Jan 6.

PMID:
30625388
31.

Donor Killer Cell Immunoglobulin-Like Receptor Genotype Does Not Improve Graft-versus-Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis.

Bachanova V, Weisdorf DJ, Wang T, Marsh SGE, Cereb N, Haagenson MD, Spellman SR, Lee SJ, Guethlein LA, Parham P, Miller JS, Cooley SA.

Biol Blood Marrow Transplant. 2019 May;25(5):949-954. doi: 10.1016/j.bbmt.2018.12.763. Epub 2018 Dec 27.

PMID:
30594542
32.

Pre-transplant recovery of microbiome diversity without recovery of the original microbiome.

Rashidi A, Kaiser T, Holtan SG, Weisdorf DJ, Khoruts A, Staley C.

Bone Marrow Transplant. 2019 Jul;54(7):1115-1117. doi: 10.1038/s41409-018-0414-z. Epub 2018 Nov 29. No abstract available.

PMID:
30498199
33.

Pretransplant Serum Citrulline Predicts Acute Graft-versus-Host Disease.

Rashidi A, Shanley R, Holtan SG, MacMillan ML, Blazar BR, Khoruts A, Weisdorf DJ.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2190-2196. doi: 10.1016/j.bbmt.2018.06.036. Epub 2018 Jul 7.

PMID:
30454871
34.

Amphiregulin in intestinal acute graft-versus-host disease: a possible diagnostic and prognostic aid.

Amin K, Yaqoob U, Schultz B, Vaughn BP, Khoruts A, Howard JR, DeFor TE, Forster C, Meyer C, Gandhi I, Weisdorf DJ, Rashidi A, MacMillan ML, Blazar BR, Panoskaltsis-Mortari A, Holtan SG.

Mod Pathol. 2019 Apr;32(4):560-567. doi: 10.1038/s41379-018-0170-z. Epub 2018 Nov 13.

PMID:
30425334
35.

Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study.

Pulsipher MA, Logan BR, Chitphakdithai P, Kiefer DM, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Bunin NJ, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Shaw BE, Confer DL.

Biol Blood Marrow Transplant. 2019 Apr;25(4):699-711. doi: 10.1016/j.bbmt.2018.11.004. Epub 2018 Nov 10.

PMID:
30423480
36.

Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors.

Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman OF, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Parameswaran V, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Confer DL, Shaw BE.

Haematologica. 2019 Apr;104(4):844-854. doi: 10.3324/haematol.2018.200121. Epub 2018 Oct 31.

37.

Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival.

Alousi A, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Pidala J, Anderlini P, Boyiadzis M, Bredeson CN, Cahn JY, Cairo MS, Gadalla SM, Hashmi SK, Gale RP, Kanda J, Kamble RT, Kharfan-Dabaja MA, Litzow MR, Ringden O, Saad AA, Schultz KR, Verdonck LF, Waller EK, Yared JA, Holtan SG, Weisdorf DJ.

Biol Blood Marrow Transplant. 2019 Feb;25(2):270-278. doi: 10.1016/j.bbmt.2018.09.004. Epub 2018 Oct 3.

PMID:
30292009
38.

Influence of Total Body Irradiation Dose Rate on Idiopathic Pneumonia Syndrome in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.

Gao RW, Weisdorf DJ, DeFor TE, Ehler E, Dusenbery KE.

Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):180-189. doi: 10.1016/j.ijrobp.2018.09.002. Epub 2018 Sep 8.

PMID:
30205123
39.

Analysis of BMT CTN-0201 and -0901 samples did not reproduce the reported association between recipient REG3A rs7588571 and chronic GVHD.

Rashidi A, Shanley R, Anasetti C, Waller EK, Scott BL, Blazar BR, Weisdorf DJ.

Bone Marrow Transplant. 2019 Mar;54(3):490-493. doi: 10.1038/s41409-018-0331-1. Epub 2018 Aug 31. No abstract available.

PMID:
30171221
40.

Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual disease-negative first complete remission.

How J, Vij KR, Ebadi M, DeFor TE, Romee R, Dolan MM, Ustun C, Weisdorf DJ, Linden MA, Rashidi A.

Am J Hematol. 2018 Dec;93(12):E381-E383. doi: 10.1002/ajh.25262. Epub 2018 Oct 9. No abstract available.

PMID:
30144151
41.

Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802.

Holtan SG, DeFor TE, Panoskaltsis-Mortari A, Khera N, Levine JE, Flowers MED, Lee SJ, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Cutler CS, Arai S, Lazaryan A, Newell LF, Jagasia MH, Pusic I, Wood WA, Renteria AS, Yanik G, Hogan WJ, Hexner E, Ayuk F, Holler E, Bunworasate U, Efebera YA, Ferrara JLM, Pidala J, Howard A, Wu J, Bolaños-Meade J, Ho V, Alousi A, Blazar BR, Weisdorf DJ, MacMillan ML.

Blood Adv. 2018 Aug 14;2(15):1882-1888. doi: 10.1182/bloodadvances.2018017343.

42.

Diffuse alveolar hemorrhage is most often fatal and is affected by graft source, conditioning regimen toxicity, and engraftment kinetics.

Keklik F, Alrawi EB, Cao Q, Bejanyan N, Rashidi A, Lazaryan A, Arndt P, Dincer EH, Bachanova V, Warlick ED, MacMillan ML, Arora M, Miller J, Brunstein CG, Weisdorf DJ, Ustun C.

Haematologica. 2018 Dec;103(12):2109-2115. doi: 10.3324/haematol.2018.189134. Epub 2018 Aug 3.

43.

Antibiotic practice patterns in hematopoietic cell transplantation: A survey of blood and marrow transplant clinical trials network centers.

Rashidi A, Wangjam T, Bhatt AS, Weisdorf DJ, Holtan SG; BMT CTN Investigators.

Am J Hematol. 2018 Nov;93(11):E348-E350. doi: 10.1002/ajh.25236. Epub 2018 Sep 9. No abstract available.

PMID:
30058189
44.

Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood.

Holmqvist AS, Chen Y, Wu J, Battles K, Bhatia R, Francisco L, Hageman L, Kung M, Ness E, Parman M, Salzman D, Wadhwa A, Winther JF, Rosenthal J, Forman SJ, Weisdorf DJ, Armenian SH, Arora M, Bhatia S.

JAMA Oncol. 2018 Dec 1;4(12):e182453. doi: 10.1001/jamaoncol.2018.2453. Epub 2018 Dec 13.

45.

Human Herpesvirus-6 Reactivation and Acute Graft-versus-Host Disease.

Rashidi A, Said B, Ebadi M, Weisdorf DJ.

Biol Blood Marrow Transplant. 2018 Nov;24(11):e5-e6. doi: 10.1016/j.bbmt.2018.07.027. Epub 2018 Jul 23. No abstract available.

PMID:
30048732
46.

Recipient single nucleotide polymorphisms in Paneth cell antimicrobial peptide genes and acute graft-versus-host disease: analysis of BMT CTN-0201 and -0901 samples.

Rashidi A, Shanley R, Yohe SL, Thyagarajan B, Curtsinger J, Anasetti C, Waller EK, Scott BL, Blazar BR, Weisdorf DJ.

Br J Haematol. 2018 Sep;182(6):887-894. doi: 10.1111/bjh.15492. Epub 2018 Jul 13.

47.

A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801.

Carpenter PA, Logan BR, Lee SJ, Weisdorf DJ, Johnston L, Costa LJ, Kitko CL, Bolaños-Meade J, Sarantopoulos S, Alousi AM, Abhyankar S, Waller EK, Mendizabal A, Zhu J, O'Brien KA, Lazaryan A, Wu J, Nemecek ER, Pavletic SZ, Cutler CS, Horowitz MM, Arora M; BMT CTN.

Haematologica. 2018 Nov;103(11):1915-1924. doi: 10.3324/haematol.2018.195123. Epub 2018 Jun 28.

48.

Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2.

Holmqvist AS, Chen Y, Wu J, Kung M, Ness E, Parman M, Francisco L, Hageman L, Battles K, Bhatia R, Salzman D, Winther JF, Rosenthal J, Forman SJ, Weisdorf DJ, Armenian SH, Arora M, Bhatia S.

Leukemia. 2018 Dec;32(12):2706-2709. doi: 10.1038/s41375-018-0171-4. Epub 2018 Jun 26. No abstract available.

PMID:
29946190
49.

161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS.

Sarhan D, Brandt L, Felices M, Guldevall K, Lenvik T, Hinderlie P, Curtsinger J, Warlick E, Spellman SR, Blazar BR, Weisdorf DJ, Cooley S, Vallera DA, Önfelt B, Miller JS.

Blood Adv. 2018 Jun 26;2(12):1459-1469. doi: 10.1182/bloodadvances.2017012369.

50.

Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect.

Rashidi A, Ebadi M, Said B, Cao Q, Shanley R, Curtsinger J, Bejanyan N, Warlick ED, Green JS, Brunstein CG, Miller JS, Weisdorf DJ.

Am J Hematol. 2018 May 14. doi: 10.1002/ajh.25141. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center